SCHEMBL1016283

SCHEMBL1016283

Cc1ccc(-c2ccc(F)cc2)cc1NC(=O)C(=O)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
HSD17B10 Q99714 1/20 0.52
SERPINE1 P05121 5/20 0.51
PTPN1 P18031 1/20 0.47
GRIK1 P39086 1/20 0.45
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 1/20 0.43
AKR1C4 P17516 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015128 0.99 KDM4E (0.51) KDM4EHSD17B10SERPINE1PTPN1GRIK1
SCHEMBL1015129 0.88 MAPT (0.42) SERPINE1PPARGPPARARXFP1MAPT
SCHEMBL1015774 0.88 ALDH1A1 (0.43) RXFP1MAPTTDP1ALDH1A1
SCHEMBL1015626 0.87 RXFP1 (0.53) KDM4EHSD17B10SERPINE1RXFP1MAPT
SCHEMBL417503 0.85 MAPT (0.64) KDM4EHSD17B10SERPINE1RXFP1MAPT
SCHEMBL1018976 0.79 PTPN1 (0.52) KDM4EPTPN1MAPTALDH1A1
SCHEMBL1016816 0.78 RXFP1 (0.46) KDM4EHSD17B10SERPINE1PTPN1RXFP1
SCHEMBL1015634 0.77 ALDH1A1 (0.53) KDM4ERXFP1MAPTTDP1ALDH1A1
SCHEMBL1016253 0.77 RXFP1 (0.45) KDM4EHSD17B10SERPINE1PTPN1RXFP1
SCHEMBL27851450 0.76 SERPINE1 (0.70) KDM4EHSD17B10SERPINE1PTPN1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 KDM4E 4108/4885HSD17B10 1898/4885SERPINE1 1/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 KDM4E 4253/4885HSD17B10 2766/4885SERPINE1 1/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 KDM4E 4348/4885HSD17B10 2794/4885SERPINE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.